GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (OTCPK:EFTR) » Definitions » Pretax Margin %

EFTR (eFFECTOR Therapeutics) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. eFFECTOR Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was $-8.83 Mil. eFFECTOR Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, eFFECTOR Therapeutics's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for eFFECTOR Therapeutics's Pretax Margin % or its related term are showing as below:


EFTR's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -127.47
* Ranked among companies with meaningful Pretax Margin % only.

eFFECTOR Therapeutics Pretax Margin % Historical Data

The historical data trend for eFFECTOR Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics Pretax Margin % Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Pretax Margin %
34.67 - - -

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of eFFECTOR Therapeutics's Pretax Margin %

For the Biotechnology subindustry, eFFECTOR Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


eFFECTOR Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's Pretax Margin % falls into.


;
;

eFFECTOR Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

eFFECTOR Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-35.811/0
= %

eFFECTOR Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-8.834/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


eFFECTOR Therapeutics  (OTCPK:EFTR) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


eFFECTOR Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


eFFECTOR Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).
Executives
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Christopher B Ehrlich director, 10 percent owner, officer: Chief Executive Officer 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Mayank Gandhi officer: Chief Business Officer 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Douglas J Warner officer: Chief Medical Officer C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075
Presidio Management Group X Llc 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Genesis Uk Llc 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004
Carlyle Investment Management Llc 10 percent owner 1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Inc. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Tc Group, Llc 10 percent owner C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004
Cg Subsidiary Holdings L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Gallagher Brian M. Jr. director, 10 percent owner C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Stephen T Worland director, officer: President and Chief Executive 9050 CAMINO SANTA FE, SAN DIEGO CA 92121

eFFECTOR Therapeutics Headlines

From GuruFocus

eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference

By Stock market mentor Stock market mentor 01-30-2023